 |
40 Products |  |
109 Diseases | | 40 Products |
|
37 Trials |  |
1900 News |  |
| «12...891011121314151617181920» |
- Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Trial primary completion date, Surgery, Metastases: Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 31, 2018
P1b/2, N=21, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Feb 2017 --> Dec 2018
- | Pegasys (pegylated interferon α -2a) / Roche
Trial primary completion date: E+VIP: Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection (clinicaltrials.gov) - Jan 25, 2018
P4, N=111, Active, not recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Feb 2017 --> Dec 2018 Trial primary completion date: Dec 2018 --> Jan 2018
- ficlatuzumab (AV-299) / LG Chem
Enrollment open, Metastases: Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Jan 23, 2018
P1b, N=30, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2018 --> Jan 2018 Not yet recruiting --> Recruiting
- | Euvax B (recombinant hepatitis B vaccine) / LG Chem
Trial primary completion date: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Jan 18, 2018
P4, N=132, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Jun 2018
- ficlatuzumab (AV-299) / LG Chem
Trial primary completion date, Metastases: FOCAL: A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (clinicaltrials.gov) - Jan 9, 2018
P2, N=10, Terminated, Sponsor: AVEO Pharmaceuticals, Inc.
Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Sep 2017 --> Jan 2017
- Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Trial primary completion date, Surgery, Metastases: Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 5, 2018
P1b/2, N=21, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Sep 2017 --> Jan 2017 Trial primary completion date: May 2017 --> Feb 2017
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) - Dec 22, 2017
P2, N=5, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: May 2017 --> Feb 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- | Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Biomarker, Journal: Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. (Pubmed Central) - Dec 16, 2017
Despite functional changes in tumor vasculature, tivozanib had limited anti-tumor activity, highlighting the limitations of anti-VEGF monotherapy. Future studies in glioblastoma should leverage the anti-vascular activity of agents targeting VEGF to enhance the activity of other therapies.
- |||||||||| Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem
Clinical: GLITTER 1: Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (clinicaltrials.gov) - Dec 13, 2017
P3, N=522, Recruiting, Sponsor: Gan and Lee Pharmaceuticals, USA
- |||||||||| Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
New P3 trial: GLITTER 2: Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (clinicaltrials.gov) - Dec 13, 2017
P3, N=554, Recruiting, Sponsor: Gan and Lee Pharmaceuticals, USA
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial primary completion date, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Dec 11, 2017
P1b, N=14, Active, not recruiting, Sponsor: James J Lee
Future studies in glioblastoma should leverage the anti-vascular activity of agents targeting VEGF to enhance the activity of other therapies. Trial primary completion date: Jun 2018 --> Jun 2016
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone (clinicaltrials.gov) - Nov 28, 2017
P1, N=70, Not yet recruiting, Sponsor: LG Chem
- | ficlatuzumab (AV-299) / LG Chem
New P1 trial, Metastases: Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Oct 20, 2017
P1b, N=30, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | LC51-0255 / LG Chem
Enrollment open: A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255 (clinicaltrials.gov) - Oct 18, 2017
P1, N=110, Recruiting, Sponsor: LG Chem
Trial primary completion date: Jun 2018 --> Jun 2016 Active, not recruiting --> Recruiting
- | Espogen (epoetin alfa biosimilar) / LG Chem
Trial completion, Enrollment change, Trial primary completion date: Erythropoietin Therapy for Children With Cerebral Palsy (clinicaltrials.gov) - Oct 12, 2017
P2, N=11, Completed, Sponsor: Bundang CHA Hospital
Active, not recruiting --> Recruiting Not yet recruiting --> Completed | N=80 --> 11 | Trial primary completion date: Dec 2015 --> Feb 2015
- || Espogen (epoetin alfa biosimilar) / LG Chem
Enrollment change, Trial primary completion date: Allogeneic UCB Therapy With EPO in Children With CP (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=92, Completed, Sponsor: MinYoung Kim, M.D.
Not yet recruiting --> Completed | N=80 --> 11 | Trial primary completion date: Dec 2015 --> Feb 2015 N=120 --> 92 | Trial primary completion date: Jul 2015 --> Jun 2017
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Oct 9, 2017
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
N=120 --> 92 | Trial primary completion date: Jul 2015 --> Jun 2017 Trial primary completion date: Dec 2017 --> Jun 2018
- | LR19122 / LG Chem
Enrollment closed: A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults (clinicaltrials.gov) - Sep 26, 2017
P1, N=42, Active, not recruiting, Sponsor: LG Chem
Trial primary completion date: Dec 2017 --> Jun 2018 Recruiting --> Active, not recruiting
- ||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment closed, Metastases: TIVO-3: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Aug 17, 2017
P3, N=322, Active, not recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | LC51-0255 / LG Chem
Enrollment closed: A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255 (clinicaltrials.gov) - Jul 19, 2017
P1, N=110, Active, not recruiting, Sponsor: LG Chem
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | LR19122 / LG Chem
Enrollment open: A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults (clinicaltrials.gov) - Jul 7, 2017
P1, N=42, Recruiting, Sponsor: LG Chem
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | LR19122 / LG Chem
New P1 trial: A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults (clinicaltrials.gov) - Jul 4, 2017
P1, N=42, Not yet recruiting, Sponsor: LG Chem
- | MIT-001 / MitoImmune Therap
New P1 trial: A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126. (clinicaltrials.gov) - Jun 22, 2017
P1, N=32, Recruiting, Sponsor: LG Chem
- | LC51-0255 / LG Chem
Enrollment open: A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255 (clinicaltrials.gov) - Jun 22, 2017
P1, N=110, Recruiting, Sponsor: LG Chem
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Trial completion, Trial primary completion date: A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols (clinicaltrials.gov) - Jun 21, 2017
P=N/A, N=225, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2015
- ficlatuzumab (AV-299) / LG Chem
Trial primary completion date: Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (clinicaltrials.gov) - Jun 9, 2017
P1, N=24, Recruiting, Sponsor: C. Babis Andreadis
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2015 Trial primary completion date: Jun 2017 --> Jun 2018
- ficlatuzumab (AV-299) / LG Chem
Enrollment change, Trial termination, Trial primary completion date, Metastases: FOCAL: A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (clinicaltrials.gov) - Jun 9, 2017
P2, N=10, Terminated, Sponsor: AVEO Pharmaceuticals, Inc.
Trial primary completion date: Jun 2017 --> Jun 2018 N=86 --> 10 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Sep 2017; Sponsor's decision
- | LC51-0255 / LG Chem
New P1 trial: A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255 (clinicaltrials.gov) - Jun 1, 2017
P1, N=110, Not yet recruiting, Sponsor: LG Chem
- Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Trial primary completion date, Surgery, Metastases: Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - May 18, 2017
P1b/2, N=21, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
N=86 --> 10 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Sep 2017; Sponsor's decision Trial primary completion date: Jul 2016 --> May 2017
- Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Trial primary completion date, Surgery, Metastases: Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - May 12, 2017
P1b/2, N=21, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jul 2016 --> May 2017 Trial primary completion date: Aug 2017 --> Jul 2016
- | Pegasys (pegylated interferon α -2a) / Roche
Enrollment closed, Enrollment change, Trial primary completion date: E+VIP: Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection (clinicaltrials.gov) - May 9, 2017
P4, N=111, Active, not recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Aug 2017 --> Jul 2016 Recruiting --> Active, not recruiting | N=150 --> 111 | Trial primary completion date: Mar 2017 --> Dec 2018
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P1/2 trial, Combination therapy, Metastases: TiNivo study : Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC (clinicaltrials.gov) - May 1, 2017
P1/2, N=32, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
- ||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Trial completion, Trial primary completion date: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Apr 26, 2017
P3, N=310, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting | N=150 --> 111 | Trial primary completion date: Mar 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016
- ||||||| Euvax B (recombinant hepatitis B vaccine) / LG Chem
Trial completion: Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. (clinicaltrials.gov) - Apr 26, 2017
P3, N=150, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016 Active, not recruiting --> Completed
- | Shinbaro (GCSB-5) / GC Pharma, LG Chem
Journal: Gastrointestinal safety and efficacy of long-term GCSB-5 use in patients with osteoarthritis: A 24-week, multicenter study. (Pubmed Central) - Apr 22, 2017
P4
The safety and efficacy profile of GCSB-5 are comparable to celecoxib. These results indicate GCSB-5 is safe for a long-term treatment of knee OA patients.
- |||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, Trial primary completion date, Metastases: RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 13, 2017
P1/2, N=56, Completed, Sponsor: Dana-Farber Cancer Institute
These results indicate GCSB-5 is safe for a long-term treatment of knee OA patients. Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2013
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Surgery: Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2013 Trial primary completion date: Jun 2016 --> Jun 2013
- | Shinbaro (GCSB-5) / GC Pharma, LG Chem
Trial completion: Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Mar 28, 2017
P=N/A, N=60, Completed, Sponsor: Jaseng Medical Foundation
Trial primary completion date: Jun 2016 --> Jun 2013 Active, not recruiting --> Completed
- || Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 27, 2017
P2, N=54, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Jan 2017 --> Jan 2018
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Jun 2017 --> Dec 2017
- | Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Enrollment closed, Enrollment change, Trial primary completion date, Surgery, Metastases: Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 24, 2017
P1b/2, N=21, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jun 2017 --> Dec 2017 Recruiting --> Active, not recruiting | N=49 --> 21 | Trial primary completion date: Mar 2017 --> Aug 2017
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment open, Trial primary completion date: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 23, 2017
P2, N=30, Recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting | N=49 --> 21 | Trial primary completion date: Mar 2017 --> Aug 2017 Suspended --> Recruiting | Trial primary completion date: Mar 2017 --> Mar 2018
- ||||| Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem
Enrollment closed: A Study Comparing LBAL to Humira (clinicaltrials.gov) - Feb 8, 2017
P3, N=380, Active, not recruiting, Sponsor: LG Life Sciences
Suspended --> Recruiting | Trial primary completion date: Mar 2017 --> Mar 2018 Recruiting --> Active, not recruiting
- Shinbaro (GCSB-5) / GC Pharma, LG Chem
Enrollment closed: Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=60, Active, not recruiting, Sponsor: Jaseng Medical Foundation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
Trial completion: PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes (clinicaltrials.gov) - Jan 26, 2017
P1, N=41, Completed, Sponsor: Gan and Lee Pharmaceuticals, USA
Recruiting --> Active, not recruiting Recruiting --> Completed
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, Trial primary completion date: Study of KRN951 in Patients With Solid Tumors (clinicaltrials.gov) - Jan 5, 2017
P1, N=12, Completed, Sponsor: Kyowa Hakko Kirin Co., Ltd
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) - Dec 22, 2016
P2, N=5, Active, not recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, Enrollment change, Trial primary completion date: Tivozanib for Recurrent Glioblastoma (clinicaltrials.gov) - Dec 2, 2016
P2, N=10, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | N=21 --> 10 | Trial primary completion date: Sep 2015 --> Sep 2014
- Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Nov 28, 2016
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
Active, not recruiting --> Completed | N=21 --> 10 | Trial primary completion date: Sep 2015 --> Sep 2014 Trial primary completion date: Dec 2016 --> Jun 2017
- |||||| TNFcept (etanercept biosimilar) / LG Chem, Mochida
Enrollment open: A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX) (clinicaltrials.gov) - Nov 22, 2016
P3, N=165, Recruiting, Sponsor: LG Life Sciences
Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Recruiting